{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:39:14Z","timestamp":1770892754330,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,12]],"date-time":"2027-02-12T00:00:00Z","timestamp":1802390400000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.hpb.2025.11.008","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:46:15Z","timestamp":1763628375000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors"],"prefix":"10.1016","volume":"28","author":[{"given":"Masaki","family":"Omori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-2473","authenticated-orcid":false,"given":"Shohei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-6761","authenticated-orcid":false,"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-8793","authenticated-orcid":false,"given":"Eisuke","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ishihda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-6084","authenticated-orcid":false,"given":"Hidetoshi","family":"Gon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-1777","authenticated-orcid":false,"given":"Takeshi","family":"Urade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-4732","authenticated-orcid":false,"given":"Hiroaki","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-1623","authenticated-orcid":false,"given":"Keitaro","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-7147","authenticated-orcid":false,"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2025.11.008_bib1","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14:","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.hpb.2025.11.008_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1030147","article-title":"The effect of organ-specific tumor microenvironments on response patterns to immunotherapy","volume":"13:","author":"Conway","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.hpb.2025.11.008_bib3","article-title":"Pan-cancer analysis identifies liver metastases as negative predictive factor for immune checkpoint inhibitors treatment outcome","volume":"12:","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hpb.2025.11.008_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70631","article-title":"Elevated neutrophil-to-lymphocyte ratio correlates with liver metastases and poor immunotherapy response in stage IV Melanoma","volume":"14:","author":"Foerster","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.hpb.2025.11.008_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2025.11.008_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, Double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2025.11.008_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2025.11.008_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hpb.2025.11.008_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1:","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.hpb.2025.11.008_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/liv.15935","article-title":"Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: a multicentre, retrospective study","volume":"44","author":"Cheon","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.hpb.2025.11.008_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/liv.15826","article-title":"Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC","volume":"44","author":"Yang","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.hpb.2025.11.008_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s12072-023-10626-6","article-title":"Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma","volume":"18","author":"Kim","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.hpb.2025.11.008_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.566297","article-title":"Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy","volume":"10:","author":"Humbert","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.hpb.2025.11.008_bib14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000501275","article-title":"Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"8","author":"Lu","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.hpb.2025.11.008_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000479984","article-title":"Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"key":"10.1016\/j.hpb.2025.11.008_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2025.11.008_bib17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hpb.2025.11.008_bib18","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hpb.2025.11.008_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12876-023-02731-5","article-title":"Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice","volume":"23","author":"Yumita","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.hpb.2025.11.008_bib20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hpb.2025.11.008_bib21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.hpb.2025.11.008_bib22","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2025.11.008_bib23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.intimp.2010.12.024","article-title":"Immunotherapeutic modulation of the suppressive liver and tumor microenvironments","volume":"11","author":"Chan","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.hpb.2025.11.008_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.hpb.2025.11.008_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hpb.2025.11.008_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41591-020-01190-9","article-title":"Liver metastases inhibit immunotherapy efficacy","volume":"27","author":"Lindblad","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hpb.2025.11.008_bib27","article-title":"Liver metastases impede checkpoint inhibitors","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hpb.2025.11.008_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hpb.2025.11.008_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001903","article-title":"Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer","volume":"9","author":"Cohen","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hpb.2025.11.008_bib30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.6004\/jnccn.2018.7059","article-title":"The adrenal gland as a sanctuary site of metastases after pembrolizumab treatment: a case series","volume":"16","author":"Nguyen","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.hpb.2025.11.008_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.imbio.2019.05.011","article-title":"Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions","volume":"224","author":"Falcon-Beas","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.hpb.2025.11.008_bib32","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2025.11.008_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25017071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25017071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:49:37Z","timestamp":1770889777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X25017071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1365182X25017071"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2025.11.008","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2025.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}